周兰教授从痰瘀互结论治中晚期卵巢癌的经验

程慧娟; 周兰

doi:10.16766/j.cnki.issn.1674-4152.003891

周兰教授从痰瘀互结论治中晚期卵巢癌的经验

doi: 10.16766/j.cnki.issn.1674-4152.003891

程慧娟^,,
周兰

蚌埠医科大学第一附属医院中医科，安徽蚌埠 233004

基金项目:

2022年度中央财政中医药事业传承与发展专项资金项目 Z155080000004

详细信息

通讯作者:
程慧娟，E-mail：214248694@qq.com

中图分类号: R737.31 R273
计量
- 文章访问数: 9
- HTML全文浏览量: 6
- PDF下载量: 1
- 被引次数: 0
出版历程
- 收稿日期: 2024-01-23
- 网络出版日期: 2025-03-27

Director Zhou Lan ' s experience in treating middle and late stage ovarian cancer based on the conclusion of phlegm and blood stasis interaction

CHENG Huijuan^,,
ZHOU Lan

Department of Traditional Chinese Medicine, the First Affiliated Hospital of Bengbu Medical University, Bengbu, Anhui 233004, China

摘要

摘要: 卵巢癌是女性高发恶性肿瘤，因病因尚不明确，且缺乏早期发现的有效方法，临床确诊时多为晚期。晚期卵巢癌复发率高，生存率低。中晚期卵巢癌的主要治疗方式是手术和化疗，可根据患者对铂类药物的敏感性分类应用铂类或非铂类药物化疗，联合抗血管生成靶向药物，根据基因检测可考虑多腺苷二磷酸核糖聚合酶(PARP)抑制剂、免疫治疗。卵巢癌中医属“癥瘕”“积聚”，周兰教授认为该病的病因病机为痰瘀互结，以活血化瘀、化痰散结为基本方法，配合清热解毒、疏肝行气、健脾养血、调摄冲任、滋阴润燥等法，治疗中晚期卵巢癌及手术、化疗、靶向、PARP药物应用后并发症的中医治疗，大大延长了患者的生存期，提高了患者的生存质量，临床疗效佳。
- 卵巢癌 /
- 痰瘀互结
Abstract: Ovarian cancer is a malignant tumor with a high incidence in women. Due to the unclear etiology and the lack of effective methods for early detection, it is mostly diagnosed in the late stage. The recurrence rate of advanced ovarian cancer is high and the survival rate is low. The main treatment modalities for advanced ovarian cancer are surgery and chemotherapy. Platinum or non-platinum chemotherapy can be classified according to the sensitivity of patients to platinum drugs, combined with anti-angiogenesis targeted drugs, and poly (ADP-ribose) polymerase (PARP) inhibitors and immunotherapy can be considered according to genetic testing. The traditional Chinese medicine of ovarian cancer refers to "lump" and "accumulation". Director Zhou Lan believes that the cause and pathogenesis of this disease are the interformation of phlegm and blood stasis. Combining the basic methods of promoting blood circulation and removing blood stasis with the methods of clearing heat and detoxification, soothing the liver and promoting qi, invigorating the spleen and nourishing the blood, regulating Chong Ren, nourishing Yin and moistening dryness, the traditional Chinese medicine treatment of the complications after surgery, chemotherapy, targeting, and PARP. The survival period of patients was greatly extended, the quality of life of patients was improved, and the clinical effect was good.
- Ovarian cancer /
- Phlegm and blood stasis intermingled

HTML全文

参考文献(17)

[1]	徐瑞华, 李进, 马军, 等. 中医临床肿瘤学会(CSIC)常见恶性肿瘤诊疗指南[M]. 北京: 人民卫生出版社, 2023: 612. XU R H, LI J, MA J, et al. Clinical Oncology Society of Traditional Chinese Medicine (CSIC) Guidelines for the diagnosis and treatment of common malignant tumors[M]. Beijing: People ' s Medical Publishing House, 2023: 612.
[2]	郭钰, 徐鹏, 王蓓蒂, 等. 血清肿瘤标志物在卵巢癌诊断中的研究进展[J]. 中华全科医学, 2021, 19(8): 1362-1366. doi: 10.16766/j.cnki.issn.1674-4152.002061 GUO Y, XU P, WANG B T, et al. Research progress of serum tumor markers in the diagnosis of ovarian cancer[J]. Chinese Journal of General Practice, 2021, 19(8): 1362-1366. doi: 10.16766/j.cnki.issn.1674-4152.002061
[3]	聂丹丹, 王丽华, 李燕华. ROMA和CPH-I在早期上皮性卵巢恶性肿瘤中的诊断价值[J]. 中华全科医学, 2022, 20(2): 190-194. doi: 10.16766/j.cnki.issn.1674-4152.002309 NIE D D, WANG L H, LI Y H. Diagnostic value of ROMA and CPH-I in early epithelial ovarian cancer[J]. Chinese Journal of General Practice, 2022, 20(2): 190-194. doi: 10.16766/j.cnki.issn.1674-4152.002309
[4]	宣跃廷, 程红. 国医大师徐经世从肝论治卵巢癌术后化疗期[J]. 中医药临床杂志, 2020, 32(1): 38-41. XUAN Y T, CHENG H. Experience of XU Jingshi in Treating Ovarian Cancer During Postoperative Chemotherapy from the Concept of "Liver"[J]. Clinical Journal of Traditional Chinese Medicine, 2020, 32(1): 38-41.
[5]	钟亮, 刘清壮, 蔡茂德. Ⅲ、Ⅳ期上皮性卵巢癌术后腹腔辅助化疗临床观察[J]. 陕西医学杂志, 2020, 49(2): 193-196. ZHONG L, LIU Q Z, CAI M D. Application of intraperitoneal chemotherapy in postoperative adjuvant treatment of stage Ⅲ and Ⅳ epithelial ovarian cancer[J]. Shaanxi Medical Journal, 2020, 49(2): 193-196.
[6]	习辉, 聂鸿雁, 张世凤. 热疗联合TC化疗治疗晚期卵巢癌的疗效及对免疫逃逸、远期预后的影响[J]. 中国性科学, 2020, 29(8): 18-21. XI H, NIE H Y, ZHANG S F. Effect of thermotherapy combined with TC chemotherapy on advanced ovarian cancer and the impact on immune escape and long-term prognosis[J]. Chinese Journal of Human Sexuality, 2020, 29(8): 18-21.
[7]	杨爽, 沈影, 韩凤娟. 中医药对卵巢癌的治疗作用及研究进展[J]. 辽宁中医杂志, 2021, 48(10): 202-207. YANG S, SHEN Y, HAN F J. Therapeutic Effect and Research Progress of Traditional Chinese Medicinal on Ovarian Cancer[J]. Liaoning Journal of Traditional Chinese Medicine, 2021, 48(10): 202-207.
[8]	马云飞, 于明薇, 李光达, 等. 肺癌血液高凝状态中西医研究进展[J]. 现代中西医结合杂志, 2020, 29(33): 3748-3752. MA Y F, YU M W, LI G D, et al. Research progress of traditional Chinese and western medicine on the hypercoagulable state of lung cancer[J]. Modern Journal of Integrated Traditional Chinese and Western Medicine, 2020, 29(33): 3748-3752.
[9]	苏云, 冯正权. 冯正权运用补肾祛瘀法治疗卵巢癌经验介绍[J]. 新中医, 2021, 53(24): 144-146. SU Y, FENG Z Q. Experience Introduction of FENG Zhengquan Treating Ovarian Cancer by Applying Kidney-Supplementing and Stasis-Dispelling Method[J]. New Chinese Medicine, 2021, 53(24): 144-146.
[10]	王芳芳, 李益萍, 蒲腾达, 等. 桂枝茯苓汤对卵巢癌术后患者外周血T淋巴细胞亚群、血清肿瘤标志物及凝血水平变化的影响[J]. 世界中医药, 2019, 14(8): 2067-2072. WANG F F, LI Y P, PU T D, et al. Effects of Guizhi Fuling Decoction on Peripheral Blood T Lymphocyte Subsets, Serum Tumor Markers in Patients with Ovarian Cancer after Operation and Coagulation Level Change[J]. World of Chinese Medicine, 2019, 14(8): 2067-2072.
[11]	李成斐, 朱萍, 于佳, 等. 益气活血解毒方联合化疗治疗晚期卵巢癌疗效及对患者免疫通路相关靶基因的影响[J]. 陕西中医, 2021, 42(8): 1072-1075, 1079. LI C F, ZHU P, YU J, et al. The effect of Yiqi Huoxie Jiedu decoction combined with TC regimen on advanced ovarian cancer and related target genes of immune pathway[J]. Shaanxi Journal of Traditional Chinese Medicine, 2021, 42(8): 1072-1075, 1079.
[12]	张夏玲, 程海波, 李柳. 基于癌毒病机理论辨治卵巢癌[J]. 北京中医药大学学报, 2023, 46(5): 736-740. ZHANG X L, CHENG H B, LI L. Differentiation and treatment of ovarian cancer based on the pathogenesis theory of cancer toxin[J]. Journal of Beijing University of Traditional Chinese Medicine, 2023, 46(5): 736-740.
[13]	李成彪, 顾刚寿. 安罗替尼三线治疗晚期卵巢癌的疗效[J]. 中华全科医学, 2023, 21(7): 1150-1152. doi: 10.16766/j.cnki.issn.1674-4152.003071 LI C B, GU G S. Efficacy of anlotinib in the third-line treatment of advanced ovarian cancer[J]. Chinese Journal of General Practice, 2023, 21(7): 1150-1152. doi: 10.16766/j.cnki.issn.1674-4152.003071
[14]	GRIGNANI G, MAIOLO A. Cytokines and hemostasis[J]. Haematologica, 2000, 85(9): 967-972.
[15]	程海波. 癌毒: 中医病机创新理论研究与应用[M]. 北京: 中国中医药出版社, 2019: 219. CHENG H B. Cancer toxicity: Theoretical research and application of TCM pathogenesis innovation[M]. Beijing: China Traditional Chinese Medicine Press, 2019: 219.
[16]	王妍, 朱广辉, 张英, 等. 从冲任论卵巢癌术后复发转移[J]. 山东中医药大学学报, 2023, 47(2): 132-133, 141. WANG Y, ZHU G H, ZHANG Y, et al. Discussion on Postoperative Recurrence and Metastasis of Ovarian Cancer from Thoroughfare and Conception Vessels[J]. Journal of Shandong University of Traditional Chinese Medicine, 2023, 47(2): 132-133, 141.
[17]	程海波. 癌毒: 中医病机创新理论研究与应用[M]. 北京: 中国中医药出版社, 2019: 218. CHENG H B. Cancer toxicity: Theoretical research and application of TCM pathogenesis innovation[M]. Beijing: China Traditional Chinese Medicine Press, 2019: 218.